1/5
07:54 am
alt
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH [Yahoo! Finance]
Low
Report
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH [Yahoo! Finance]
1/5
07:30 am
alt
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH
Medium
Report
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH
12/19
07:02 am
alt
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial [Yahoo! Finance]
High
Report
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial [Yahoo! Finance]
12/19
06:30 am
alt
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial
High
Report
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial
12/1
07:44 am
alt
Altimmune announces CEO transition [Seeking Alpha]
Medium
Report
Altimmune announces CEO transition [Seeking Alpha]
12/1
07:30 am
alt
Altimmune Announces CEO Transition and Succession Plan
Medium
Report
Altimmune Announces CEO Transition and Succession Plan
11/26
07:53 am
alt
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Low
Report
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
11/26
07:30 am
alt
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference
Low
Report
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference
11/12
08:46 am
alt
Altimmune (NASDAQ:ALT) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Altimmune (NASDAQ:ALT) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
11/11
09:21 am
alt
Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025 [Yahoo! Finance]
Low
Report
Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025 [Yahoo! Finance]
11/11
08:51 am
alt
Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025
Low
Report
Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025
11/7
09:27 am
alt
Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025 [Yahoo! Finance]
Medium
Report
Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025 [Yahoo! Finance]
11/7
08:41 am
alt
Altimmune (NASDAQ:ALT) had its price target lowered by analysts at Citizens Jmp from $15.00 to $14.00. They now have a "market outperform" rating on the stock.
Medium
Report
Altimmune (NASDAQ:ALT) had its price target lowered by analysts at Citizens Jmp from $15.00 to $14.00. They now have a "market outperform" rating on the stock.
11/7
08:05 am
alt
Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025
Medium
Report
Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025
11/6
07:00 am
alt
Altimmune Announces Third Quarter 2025 Financial Results and Business Updates
Medium
Report
Altimmune Announces Third Quarter 2025 Financial Results and Business Updates
11/5
07:30 am
alt
Altimmune to Participate in Two Upcoming Investor Conferences
Low
Report
Altimmune to Participate in Two Upcoming Investor Conferences
11/3
07:30 am
alt
Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder
Low
Report
Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder
10/30
07:30 am
alt
Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025
Low
Report
Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025
10/20
08:08 am
alt
Altimmune (NASDAQ:ALT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Medium
Report
Altimmune (NASDAQ:ALT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
10/20
07:30 am
alt
Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025
Medium
Report
Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025